Edition:
India

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

5.28USD
23 Aug 2019
Change (% chg)

$-0.12 (-2.22%)
Prev Close
$5.40
Open
$5.44
Day's High
$5.46
Day's Low
$5.20
Volume
388,638
Avg. Vol
290,546
52-wk High
$7.80
52-wk Low
$4.49

Latest Key Developments (Source: Significant Developments)

Cerus Corp Reports Q2 Loss Per Share $0.13
Friday, 2 Aug 2019 

Aug 1 (Reuters) - Cerus Corp ::CERUS CORPORATION ANNOUNCES RECORD SECOND QUARTER 2019 RESULTS.Q2 LOSS PER SHARE $0.13.Q2 REVENUE $22.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $22.3 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.RAISING 2019 FULL YEAR PRODUCT REVENUE GUIDANCE TO A RANGE OF $72 MILLION TO $75 MILLION.  Full Article

Cerus Corporation Q1 Loss Per Share $0.14
Wednesday, 8 May 2019 

May 7 (Reuters) - Cerus Corp ::ANNOUNCES RECORD FIRST QUARTER 2019 RESULTS.Q1 LOSS PER SHARE $0.14.Q1 REVENUE $22 MILLION VERSUS REFINITIV IBES ESTIMATE OF $20.9 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.2019 FULL YEAR PRODUCT REVENUE GUIDANCE BEING RAISED TO RANGE OF $71 MILLION TO $74 MILLION FROM $70 MILLION TO $73 MILLION.QTRLY GOVERNMENT CONTRACT REVENUE OF $4.5 MILLION.  Full Article

Cerus Reports Q4 Results
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - Cerus Corp ::ORATION ANNOUNCES RECORD FOURTH QUARTER AND FULL YEAR 2018 RESULTS.Q4 LOSS PER SHARE $0.12.Q4 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.2019 ANNUAL PRODUCT REVENUE GUIDANCE OF $70 MILLION TO $73 MILLION.QTRLY PRODUCT REVENUE $16.5 MILLION VERSUS $16.2 MILLION.  Full Article

Cerus Announces The Fourth Biologics License Application Approval For A U.S. Blood Center Customer
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Cerus Corp ::CERUS ANNOUNCES THE FOURTH BIOLOGICS LICENSE APPLICATION (BLA) APPROVAL FOR A U.S. BLOOD CENTER CUSTOMER.CERUS- COMMUNITY BLOOD CENTER OF APPLETON, WISCONSIN RECEIVED APPROVAL BY FDA ON BLA REQUESTING ALLOWANCE OF INTERSTATE DISTRIBUTION OF PLATELETS.  Full Article

Cerus Corp Reports Q4 Loss Per Share $0.10
Friday, 9 Mar 2018 

March 8 (Reuters) - Cerus Corp ::ORATION REPORTS RECORD FOURTH QUARTER AND YEAR END 2017 RESULTS.Q4 LOSS PER SHARE $0.10.Q4 EARNINGS PER SHARE VIEW $-0.11 -- THOMSON REUTERS I/B/E/S.‍REPORTED Q4 PRODUCT REVENUE OF $16.2 MILLION, AN INCREASE OF 60% COMPARED TO SAME PERIOD IN YEAR PRIOR​.  Full Article

Cerus Announces Pricing Of Public Offering Of Common Stock
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - Cerus Corp ::CERUS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.CERUS CORP - ‍PRICING OF PUBLIC OFFERING OF ITS COMMON STOCK FOR PROCEEDS OF $50.0 MILLION, BEFORE DEDUCTING ESTIMATED OFFERING EXPENSES PAYABLE BY CERUS​.  Full Article

Cerus Corp Expects Full Year 2017 Product Revenue To Be $43.6 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cerus Corp ::CERUS CORP - CERUS' UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION.CERUS CORP - UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION.CERUS CORP - EXPECTS FULL YEAR 2017 PRODUCT REVENUE TO BE $43.6 MILLION.CERUS CORPORATION ANNOUNCES PRELIMINARY PRODUCT REVENUE RESULTS FOR FOURTH QUARTER AND FULL YEAR 2017.  Full Article

Cerus Corp reports Q3 loss per share $0.12
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Cerus Corp :Cerus Corp reports third quarter 2017 results.Q3 loss per share $0.12.Q3 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.Cerus Corp - ‍product revenue for q3 of 2017 was $10.8 million, up 6 pct compared to $10.2 million recognized during same period in 2016​.  Full Article

Cerus and Kedrion Biopharma enter distribution agreement for full INTERCEPT blood system portfolio
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cerus Corp :Cerus and Kedrion Biopharma enter distribution agreement for the full INTERCEPT blood system portfolio in Italy.Says ‍entered into an agreement with Kedrion Biopharma to distribute full complement of INTERCEPT blood system products in italy​.Says ‍Kedrion Biopharma will be sole distributor for intercept blood systems in Italy​.Says ‍kedrion Biopharma will have right to distribute INTERCEPT red blood cells following CE mark approval​.  Full Article

Cerus announces agreement with transfusion Center of the Community of Madrid
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Cerus Corp :Cerus announces agreement with transfusion Center of the Community of Madrid.Entered into a supply agreement with Centro de transfusión de la Comunidad de Madrid (CTCM) for intercept blood system for platelets​.  Full Article